What Are AML Induction & Consolidation Therapies?

When you are suddenly diagnosed with Acute Myeloid Leukemia (AML), the fast-paced, life-altering nature of the news can feel incredibly overwhelming. To give you a clear roadmap, your treatment plan is typically divided into two main, sequential phases: induction and consolidation (often followed by a third phase called maintenance). The goal of induction therapy is to get you into remission by clearing the obvious leukemia cells from your body ^[1]. Once remission is achieved, the goal of consolidation therapy is to keep you in remission by destroying any hidden, microscopic leukemia cells that were left behind ^[2][3]. Together, these phases form the foundation of most AML treatment plans.

Induction Therapy: Getting Into Remission

Induction is the first phase of your AML treatment. It is an intensive, fast-paced step designed to quickly clear the leukemic blasts (immature, abnormal leukemia cells) from your blood and bone marrow ^[1][4]. The goal is to achieve complete remission (CR), which means less than 5% of the cells in your bone marrow are blasts, and your normal blood cell counts have returned to safe levels ^[5][6].

Depending on your age, overall health, and the specific genetic makeup of your AML, your doctor will recommend an approach that may include targeted therapies (drugs that attack specific gene mutations like FLT3 or IDH) alongside one of the following main paths:

• Intensive Chemotherapy: The standard intense approach is often called the “7+3” regimen ^[7]. This involves a combination of two chemotherapy drugs—cytarabine given continuously for 7 days, and an anthracycline (like daunorubicin) given for 3 days ^[7]. Because this treatment is very strong, it requires you to be hospitalized for about 3 to 4 weeks while your immune system recovers. You can expect severe fatigue, a high risk of infections, and the need for regular blood transfusions ^[8].
• Non-Intensive Therapy: For older patients or those with other medical conditions, doctors may recommend a targeted drug like venetoclax combined with a less intense medication, such as a hypomethylating agent (a drug that changes how genes work to help abnormal cells mature and die naturally) or low-dose cytarabine ^[7][9]. This approach has become a standard way to achieve remission without the harshest side effects of intensive chemotherapy, often requiring less time in the hospital ^[10].

After induction, your care team will perform a bone marrow biopsy to check if you have reached complete remission ^[1]. If the first round does not eliminate enough blasts, do not panic—your doctor will discuss next steps, which may include a second round of induction (re-induction) or switching to different medications ^[1][11].

Consolidation Therapy: Staying In Remission

Even if your bone marrow test shows you are in complete remission, microscopic leukemia cells almost always remain hiding in the body. This is called measurable residual disease (MRD) ^[2][12]. If left untreated, these tiny amounts of leukemia will likely multiply and cause the cancer to return (relapse) ^[2][12].

Consolidation therapy (also called post-remission therapy or intensification) is the second phase of treatment, meant to destroy this hidden residual disease and prevent a relapse ^[2][3]. Your doctor will check your MRD status using advanced tests, and this information, along with your genetic risk profile, will guide your consolidation options ^[2][13].

The two most common approaches to consolidation are:

• More Chemotherapy: Patients with a lower risk of relapse often receive additional cycles of chemotherapy ^[14]. A common regimen is HiDAC (high-dose cytarabine), which uses larger doses of the drug than you received during induction to help eliminate any remaining leukemia cells ^[14][15].
• Stem Cell Transplant: For patients at a higher risk of relapse, or those who still have MRD after induction, the standard approach is an allogeneic hematopoietic stem cell transplant (allo-HSCT) ^[14][15]. This intensive procedure replaces your diseased bone marrow with healthy blood-forming stem cells from a donor ^[16]. It requires a significant hospital stay and a long recovery period at home. The goal is to create a new immune system that can recognize and attack any remaining leukemia cells ^[2][17].

Looking Ahead: Maintenance Therapy

In modern AML care, many patients move into a third phase called maintenance therapy after completing consolidation ^[2]. This involves taking ongoing, lower-intensity treatments (such as oral medications or targeted inhibitors) to help keep the leukemia away for as long as possible, particularly for patients who do not undergo a stem cell transplant.